Full text is available at the source.
Abstract
Neuro-PASC patients exhibit distinct immunological signatures with elevated responses to SARS-CoV-2 Nucleocapsid protein at an average of 6 months post-infection.
- Elevated humoral and cellular immune responses were observed in Neuro-PASC patients compared to healthy COVID convalescents.
- Neuro-PASC patients showed increased production of IL-6 and decreased activation of CD8T cells.
- Cognitive deficits and quality of life disturbances in Neuro-PASC patients correlated with reduced diversity of effector molecule expression in T cells.
- Higher levels of IFN-γ production in response to the C-terminal domain of Nucleocapsid protein were noted in Neuro-PASC patients.
- Proteomics analysis revealed enhanced plasma immunoregulatory proteins and reduced pro-inflammatory and antiviral proteins in Neuro-PASC patients, associated with worse neurocognitive dysfunction.
Simplified